Hepatitis C virus (HCV) is a major chronic disease that has infected greater than 150 million people worldwide. Given the breadth and duration of infection HCV disease could result in an economic crisis reaching into the 100s of billions within the next decade. Although acute infection is usually asymptomatic with self-resolution, 55--85% of infected persons develop chronic disease that can lead to progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (HCC; [@B43]) which is often fatal without treatment. There is also a strong association of HCV infection with extra-hepatic diseases such as cryoglobulinemia vasculitis ([@B60]), diabetes ([@B70]), thyroid disease ([@B79]), lichen planus ([@B49]), and neuropsychiatric conditions such as depression ([@B97]). This is complicated by the fact that approximately only half of individuals are aware of their HCV status ([@B29]), due, at least in part, to the rarity of symptoms in acute HCV infection. In 2007, mortality due to HCV infection surpassed that of HIV in the United States ([@B61]).

HCV DISEASE IN HUMANS
=====================

Hepatitis C virus was first identified by [@B26] as the etiologic agent of non-A, non-B hepatitis. HCV is an enveloped, single-stranded, positive sense RNA virus belonging to the *Hepacivirus* genus within the *Flaviviridae* family. The genome is 9.6 kb with a single open reading frame (ORF) that encodes a polyprotein which is further cleaved to yield 10 mature viral proteins namely the structural proteins (C, E1, E2) and non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B; [@B42]; [@B59]). The envelope proteins (E1 and E2) and NS1 are encoded from the most variable regions of the HCV genome while NS5B codes for the RNA-dependent RNA polymerase (RdRp) that is more highly conserved. HCV strains are classified into seven genotypes and 67 subtypes ([@B91]) based on sequence heterogeneity. Genotypes 1 and 2 are distributed globally while genotype 3 predominates in Southeast Asia, genotype 4 in most of Africa, genotype 5 in South Africa, and genotype 6 primarily in Hong Kong and Vietnam ([@B40]). A genotype 7 variant has been confirmed in only one Canadian patient who had emigrated from the Democratic republic of Congo ([@B74]; [@B91]). In the US, 70% of HCV infections are due to genotype 1 ([@B40]). Transmission of HCV occurs primarily through exposure to HCV-infected blood with an average incubation period of 6--10 weeks ([@B5]; [@B8]). Increased alanine aminotransferase (ALT) levels, as a marker for liver damage, are also observed within 8--12 weeks after exposure ([@B83]). Many individuals clear the virus within 6--12 months, but the outcome of the infection depends on multiple factors including host genetics, virus strain, and virus-specific immunity ([@B1]). Ethnicity, sex, alcohol abuse, and co-infections can also contribute to the outcome of infection ([@B98]; [@B88]; [@B7]). However, the full spectrum of factors that dictate clearance versus chronicity remains unknown.

Traditionally, therapy for chronic HCV has utilized a combination of pegylated-IFN-α and ribavirin ([@B67]; [@B38]), and later direct-acting antivirals Boceprevir and Telaprevir in combination with pegylated IFN-α and ribavirin ([@B48]; [@B82]). Recently, Sofosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor developed by Gilead, has been approved as part of an antiviral regimen ([@B51]). This represents a breakthrough in HCV therapeutics since Sofosbuvir is a simplified once-daily oral treatment ([@B24]; [@B51]). However, the high cost and sophisticated clinical monitoring required will likely make implementation challenging in developing countries.

Despite two decades of research, no vaccine for HCV is available. Several candidate vaccines that reached the stage of Phase I or II clinical trials did not progress further ([@B106]; [@B109]). One of the major challenges (summarized in **Table [1](#T1){ref-type="table"}**) for vaccine development is the lack of small animal models that would allow the study of HCV infection, genetic variability of host defenses, and immune modulatory mechanisms induced by the virus. GBV-B is phylogenetically a close relative of HCV and infects only New World monkeys such as tamarins and marmosets ([@B73]; [@B77]). Although GBV-B causes acute hepatitis with few cases of persistence, it has been used as a surrogate model for HCV infection in various studies to understand pathogenesis and to demonstrate candidate antiviral activity ([@B10], [@B11]; [@B13]; [@B46]). Even the differential infection profiles between the two viruses could prove helpful in grasping the immune evasion strategies of HCV. For example, the HCV non-structural protein 5A (NS5A), implicated in establishing persistence, modulates the Ras-Erk signaling pathway ([@B65]), whereas the GBV-B NS5A protein does not block this pathway and also differs in its cellular distribution ([@B66]). This suggests that the altered mechanism of NS5A in HCV infection could be responsible for the chronicity of HCV in humans. Thus, both the similarities and the contrasts of the GBV-B model with the HCV infection can serve to broaden the knowledge of HCV pathogenesis.

###### 

Challenges in study and control of HCV.

  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------
  Genetic diversity of the virus    Genotypes are at least 30% divergent in nucleotide sequence Quasispecies variation introduced by error prone RNA dependent RNA polymerase (RdRp)
  Propagation of virus *in vitro*   Difficulty in isolation and propagation of HCV in cell lines
  Vaccine development               Limited human studies in HCV at-risk populations Lack of suitable animal models to understand viral pathogenesis and execute vaccine studies
  Treatment                         Expensive, limited availability
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------

HISTORY OF GBV-B
================

In an attempt to isolate and identify the etiologic agent(s) responsible for non-A, non-B hepatitis, [@B27] inoculated tamarins and marmosets with the sera from patients with severe hepatitis. The serum from one individual, a surgeon whose initials were GB, was found to cause hepatitis in four challenged tamarins. Serial passages of the infected tamarin sera also caused hepatitis in some animals. The 11th passage of this serum (H205 GB pass 11 serum) was demonstrated to be infectious in most tamarins and later was used as the primary virus source for subsequent studies ([@B28]; [@B73]; [@B90]; [@B17], [@B16]). Interestingly, the H205 GB pass 11 serum was found to be non-infectious in chimpanzees ([@B95]). Reciprocally, tamarins were not infected by HCV ([@B39]) implying that the GB infectious agent and HCV are different entities.

In [@B90] two viruses were identified from the serum of a tamarin infected with the H205 GB pass 11 serum and were termed GBV-A and GVB-B. The genomic structure of both the GB agents were similar to the *Flaviviridae* family of viruses. GBV-B in particular was found to be closely related to HCV based on amino acid sequence alignments and phylogenetic analyses (**Table [2](#T2){ref-type="table"}**; [@B73]). A third virus, GBV-C, was also identified in human serum samples by the usage of degenerate oligonucleotides that amplify related viral sequences ([@B89]). GBV-C was later determined to be the same virus as hepatitis G virus (HGV; [@B58]). GBV-A was identified as a common primate virus with viral genomes identified in *Sanguinus*, *Callithrix,* and *Aotus* species ([@B15]). GBV-A does not appear to cause hepatitis, but can persistently infect New World monkeys with no obvious disease symptoms ([@B15]). Phylogenetic analysis showed that HCV and GBV-B were closely related while GBV-A and GBV-C form a separate cluster ([@B73]; [@B89]). The GBV-A and GBV-C viruses have now been classified under a different genus, *Pegivirus*, and renamed as simian pegivirus (SPgV) and human pegivirus (HPgV) respectively ([@B92]). Unlike GBV-A, GBV-B is not commonly found in New World monkeys and its natural host range is still unknown. Experimental inoculation with GBV-B results in elevated liver enzymes in tamarins and can afford protection against GBV-B re-infection ([@B87]). Further, development of acute hepatitis in tamarins by transfection studies with RNA transcripts of an infectious clone of GBV-B confirmed the hepatotropism of GBV-B ([@B17]).

###### 

Hepatitis C virus and related flaviviruses.

                          Nucleotide sequence homology to HCV based on NS3 and NS5b genes   Disease characteristics
  ----------------------- ----------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  **Hepacivirus**                                                                           
  GBV-B                   48--62% ([@B73])                                                  Infects New World monkeys; hepatotrophic; acute hepatitis; spontaneous clearance in most cases ([@B92])
  CHV                     50% ([@B50]; [@B80])                                              Infects dogs; not associated with liver disease; virus found in nasal samples
  NHPV (CHV-like virus)                                                                     Infects horses; associated with acute and chronic infection of liver ([@B80])
  **Pegivirus**                                                                             
  GBV-A                   53--55% ([@B73])                                                  Infects New World monkeys; lymphotrophic; life-long infection; no apparent disease ([@B92])
  GBV-C                   40--50% ([@B58])                                                  Infects humans; lymphotrophic; persistent infection; no evidence of liver damage ([@B92])
  GBV-D                   41% ([@B32])                                                      Infects bats; no apparent hepatic dysfunction ([@B32])

OTHER HEPACIVIRUSES
===================

The origin of HCV in humans is still not completely understood as no HCV or HCV-like viruses have been discovered in Old World monkeys. To understand the evolutionary origin of HCV and to identify and characterize animal viral homologs (**Table [2](#T2){ref-type="table"}**), the sera of multiple non-primate species were screened for the presence of hepaciviruses ([@B18]). Canine hepacivirus (CHV), which has just 50% nucleotide sequence divergence from HCV, was found to cause a respiratory disease in dogs associated with high virus replication in the respiratory tract ([@B50]). Serological analysis revealed the presence of virus variants similar to CHV in horses, termed as non-primate hepaciviruses (NPHVs), with rates of persistence greater than 20% and that cluster with the canine/equine clade ([@B18]). Acute and chronic hepatitis has been associated with NHPV infection in horses with greater than 60% clearance of infection within first 2 months of infection ([@B80]). Novel hepaciviruses have also been isolated from European bank voles and South African four-striped grass mice and although these viruses are related to GBV-B their ability to cause disease remains to be determined ([@B31]).

MODELS OF HCV INFECTION
=======================

CHIMPANZEE
----------

Chimpanzees (*Pan troglodytes*) were the first animal model for HCV infection and have contributed significantly to understanding the natural history of HCV ([@B44]; **Table [3](#T3){ref-type="table"}**). Chimpanzees also played a critical role in discovery of HCV ([@B4]), and in the absence of efficient cell culture systems, most infectious clones of HCV were developed *in vivo* ([@B52]; [@B107]). Chimpanzees have also been the primary model for evaluation of various antivirals and vaccine modalities ([@B25]; [@B35]; [@B21]; [@B93]; [@B20]). Similar to HCV infection in humans, infection of chimpanzees can result in either an acutely cleared disease or chronic infection ([@B99]; [@B64]). Acute infection is characterized by early appearance of viremia (within a week) reaching peak viral titers of 10^5^--10^7^ genome copies/ml in plasma ([@B99]; [@B14]). Antibodies against HCV protein are generally detected within the first 2 months of infection ([@B14]). Hepatitis is evidenced by elevated serum liver enzyme values and necroinflammatory changes in the liver. Approximately 60% of infected chimpanzees develop chronic disease ([@B2]), characterized by persistent viremia and mild hepatitis. Unfortunately, the use of chimpanzees as an animal model for HCV continues to be limited due to their low availability, high expense, ethical concerns, and a disease course significantly attenuated compared to humans ([@B14]).

###### 

Animal models for HCV.

  Model                                           Advantages                                                      Limitations
  ----------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------------
  Chimpanzee                                      HCV discovery; *in vivo* virus replication                      Expensive; limited availability; lack of liver fibrosis; low chronicity rate; ethical concerns
  Tree shrew                                      Small animal model susceptible to HCV infection                 Lack of chronicity; only transient viremia
  Humanized mice model                            Useful for immunization and challenge studies                   Low level of viral replication; lack of progressive liver pathology
  GBV-B infection of New World monkeys            GBV-B closely related to HCV; analogous disease course to HCV   Low frequency of chronic disease
  Chimeric GBV-B infection of New World monkeys   Antiviral testing                                               Inability to cause chronic infection

TREE SHREW
----------

The northern tree shrew (*Tupaia belangeri*) is a non-rodent small mammal indigenous to Southeast Asia, and other than chimpanzees and humans, tree shrews are the only other species known to be susceptible to HCV infection ([@B105]). In a 3-year longitudinal study ([@B6]) persistent liver infection was found in some animals and included some histological indications of liver disease such as steatosis, fibrosis, and cirrhosis. Viremia and serum antibody levels were intermittent, and in general the course of infection was transient and self-resolving. Although infected tree shrews have been used for metabolomic analyses to identify biomarkers associated with HCV infection ([@B94]), the limited virus replication and lack of species-specific reagents make tree shrews unlikely to become a viable model (**Table [3](#T3){ref-type="table"}**).

MOUSE MODELS
------------

Although mice are naturally resistant to HCV infection, humanized chimeric mice with normal human hepatocytes exhibit prolonged infection following inoculation with HCV ([@B71]). This model has been very helpful for preliminary antiviral drug evaluation, but offers little for the study of HCV pathogenesis since the chimeric mice are immunodeficient. [@B81] generated transgenic mice expressing human CD81, scavenger receptor type B class1, claudin 1, and OCLN and infected them with HCV. This humanized model allowed for the investigation of HCV co-receptor biology *in vivo* using antibodies against CD81 and E2 to inhibit viral entry, but was limited by inefficient replication and induction of immune responses against the adenovirus vector, which was used to express the human receptors (**Table [3](#T3){ref-type="table"}**).

CHARACTERISTICS/NATURAL HISTORY OF GBV-B INFECTION
==================================================

VIROLOGY
--------

Similar to HCV, GBV-B has a positive-sense single stranded RNA genome and a single ORF encoding the structural (core, E1 and E2 proteins) and the non-structural (p13, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) proteins ([@B73]). The non-structural proteins are essential for replication, as is the 5′ UTR that directs translation and release of the viral RdRp initiating replication ([@B30]; [@B100]). Similar to the p7 protein of HCV, GBV-B also has a 13-KDa protein, p13, located between E2 and NS2 that is essential for viability ([@B96]). Only short regions of nucleotide sequence similarity are shared by GBV-B and HCV including a 130-nucleotide segment of 62% homology in the NS3 region and a 516-nucleotide segment of NS5 of 68% homology ([@B73]). The polyproteins of HCV and GBV-B have approximately 25--30% homology at the amino acid level, but the 5′ and 3′ UTR are more distinct ([@B73]; [@B84]). The NS2 protein of GBV-B shares membrane topology and has cysteine protease activity similar to HCV ([@B12]). At a functional level, the NS3 protease of GBV-B can correctly process the HCV polyprotein ([@B86]) and HCV/GBVB chimeric NS3 proteins are enzymatically active ([@B19]). Interestingly, while both HCV and GBV-B NS5A proteins activate the p13 kinase pathway, HCV NS5A blocks the Ras-Erk pathway, whereas GBV-B NS5A does not ([@B63], [@B62]; [@B66]). Despite an error-prone RdRp, very few amino acid substitutions have been observed, limiting the quasispecies variation of GBV-B in infected animals ([@B69]). Unlike HCV, no hypervariable region was found in the E2 gene of GBV-B in a study by [@B75] and [@B69] calculated the mutation rate of GBV-B to be 0.6 × 10^-3^ nucleotide substitutions/site/year. By comparison, the error rate for HCV RdRp has been estimated at 1.4 to 1.9 × 10^-3^ nucleotide substitutions/genome/site/year ([@B76]; [@B78]). These virological differences likely account for the significant differences in quasispecies diversity when comparing GBV-B and HCV.

PATHOGENESIS
------------

GB virus B is hepatotropic, but has been shown to disseminate to hematolymphoid and genital tissues, including lymph nodes, spleen, PBMC, kidney, testis, and bone marrow ([@B45]), much like HCV. The course of experimental GBV-B infection in New World monkeys usually results in acute hepatitis that resolves within 2--3 months post-infection with significant increases in serum enzymes such as ALT and isocitrate dehydrogenase ([@B55]; [@B13]; [@B101]). GBV-B infection leads to a rapid rise in viremia reaching peak levels of 10^7^--10^10^ genomic equivalents (GEs)/ml by weeks 2--3 and then plateaus before clearance ([@B47]; [@B104]). Different from HCV, the liver enzyme glutamate dehydrogenase has been shown to be associated with viral clearance and hepatocyte destruction, rather than serum ALT levels ([@B13]). In liver, degeneration and apoptosis of hepatocytes and disruption and dilation of sinusoids have been observed pathologically in GBV-B infected animals ([@B68]; [@B47]). In a marmoset study by [@B101], two disease phenotypes were observed -- susceptible and partially resistant. Upon further passaging, the GBV-B virus was able to adapt even in partially resistant animals. GBV-B also infects owl monkeys of the *Cebidae* family but pathogenesis is significantly attenuated as indicated by peak viral titer 2--3 logs lower and milder hepatitis as compared to tamarins and marmosets ([@B16]).

VIRUS PERSISTENCE
-----------------

A major difference between HCV and GBV-B infections is the chronic nature of HCV (**Table [3](#T3){ref-type="table"}**). Generally GBV-B causes an acute infection, although a few cases of chronicity have been reported. Viral persistence for 2 years has been reported in a tamarin infected by intrahepatic inoculation with a synthetic viral RNA before spontaneous resolution ([@B68]). In another study transfection with a poly (U) tract deletion mutant rendered a tamarin persistently infected until its death at week 90, whereas in other tamarins, acute resolving infection with clearance at week 12 was observed ([@B75]). In infected marmosets ([@B47]), early peak viremia was followed by clearance within 8 weeks in some animals whereas other animals with delayed peak viral load remained viremic up to 6 months. Similarly, [@B46] showed that two out of four marmosets infected with a molecular clone, pGBB, developed long-term chronic infection for up to 3 years with recurrent viremia at low levels, similar to chronic infections in chimpanzees. In efforts to increase persistence in the GBV-B model, immunosuppressive drugs have been utilized. Treatment with FK506 in marmosets prior to GBV-B inoculation resulted in higher viral loads and severe liver pathology but did not lead to viral persistence ([@B47]). In most infection studies that showed viral persistence, virus from persistently infected animals did not result in chronic infections when transferred to other recipients. This suggests that persistence may be primarily dependent on individual host factors.

IMMUNOLOGY
----------

One of the first responses to HCV infection in the liver is induction of type I interferons that are thought to aid in viral clearance. However, HCV inactivates early innate antiviral defenses via its NS3/4A protease, which has been postulated to lead to persistence ([@B37], [@B36]; [@B56]; [@B72]). Similarly, the GBV-B NS3/4A protease inhibits IFN-inducing pathways, notably RIG-I signaling ([@B23]). When primary hepatocyte cultures were exposed to IFN-α prior to GBV-B infection, potent antiviral activity blocked virus infection ([@B22]). By comparison, in cultures with pre-established GBV-B infection there was reduced antiviral activity, suggesting replicating virus could exert anti-IFN actions.

Much like HCV, T cell immunity has been correlated with viral clearance in marmosets infected with GBV-B ([@B104]). Virus-specific T cells were detected in blood at 7 weeks post-infection, coinciding with viral clearance and GBV-B specific IFN-γ responses at week 5 post-infection coincided with a 100-fold reduction in viral load. Virus-specific T cells have also been found to accumulate in the liver of infected marmosets, and the majority of the T cell responses (based on IFN-γ ELIspot) are generated against epitopes in the NS3 and NS4A proteins ([@B104]). Upon re-infection of marmosets, the sharp increase in the T cell response suggests the mobilization of memory T cell responses even though no take of infection was observed ([@B104]). In marmosets infected with a molecular clone of GBV-B, persistent viremia for 6 months was accompanied by marked influx of MHC class I restricted CD8^+^ T lymphocytes associated with hepatic pathology ([@B47]). This is in agreement with studies that have shown predominance of CD8^+^ T cells in the liver during chronic HCV contributing to liver injury ([@B34]).

Unlike T cell immunity, the humoral response to GBV-B infection is less well-characterized. Anti-NS3 antibody production peaks toward the end of infection and declines following clearance ([@B10]). The antibody levels fall rapidly in the absence of viral replication ([@B10]), which is similar to chimpanzees infected with HCV ([@B9]). However, in multiple instances a delayed antibody response has been associated with GBV-B persistence ([@B68]; [@B46]).

GBV-B CHIMERAS
==============

Attempts to improve on the GBV-B model have resulted in construction of chimeric viruses where functional segments of the HCV genome have been incorporated while retaining the ability of GBV-B to replicate and cause liver disease in small primates. These chimeras are extremely valuable for testing candidate therapeutics by targeting specific HCV sequences, but their utility has been marred by difficulties in maintaining efficient take of virus and persistent replication. In HCV infection the IRES directly binds to 40S ribosomal subunit and is a prime candidate target for drug therapeutics. [@B85] constructed a chimeric RNA encoding domain III from the HCV IRES element and while the virus was found to be replication competent, replication levels were generally low and generated adaptive mutations that were necessary for efficient replication. The same chimeric infection in marmosets displayed wide-ranging phenotypes from susceptible to resistant as seen in wild-type GBV-B infection ([@B102]). Unlike wild-type virus, the chimeric virus failed to adapt in the resistant marmosets on serial passages, indicating loss of fitness ([@B102]). The first 27 to 31 N-terminal amino acids of the HCV E2 protein hypervariable region 1 (HVR1) have a high degree of sequence variability between different HCV isolates ([@B103]; [@B53]; [@B3]), and have been suggested to contain a dominant neutralizing epitope ([@B33]). [@B41] generated a chimeric GBV-B encoding the HVR1 of HCV and were able to demonstrate successful infection *in vivo*. However, marmosets cleared the virus as early as 3 weeks post-infection and therefore it was not possible to generate anti-HVR1 antibodies in these animals. Recently, [@B57] generated GBV-B chimeras containing full-length HCV genes of either whole structural core or all envelope proteins. Infected marmosets remained viremic up to 44 weeks and exhibited significant liver pathology and a strong T cell response. Given the restricted tropism of HCV to humans and chimpanzees, the capability of this chimera with HCV envelope proteins to infect marmosets and primary marmoset hepatocyte cultures could suggest conserved viral receptors and virus--host interactions.

GBV-B DRUG TESTING MODELS
=========================

The GBV-B infection model has also been used for the screening of candidate vaccines and other therapeutic agents such as interferon and ribavarin. Ribavarin treatment reduced viral RNA levels by four logs by inducing error prone replication in culture, but *in vivo* treatment showed no obvious reduction in viremia ([@B54]). [@B13] demonstrated the efficacy of HCV antivirals against GBV-B by showing that HCV NS3 protease inhibitors could block replication both *in vitro* and *in vivo*. Furthermore, a *trans*-lactam, GW0014X was also found capable of preventing GBV-B infection in marmosets. RNA interference, used in gene silencing, has also been applied therapeutically in GBV-B-infected animals. Marmosets administered cationic liposome-encapsulated siRNA (CLsiRNA) directed against GBV-B virus controlled virus replication in manner dependent on CL-siRNA dosing, reaching levels of complete inhibition at 5 mg/kg ([@B108]).

CONCLUDING REMARKS
==================

During the last decade various reports have shown the utility of GBV-B infection as a surrogate model for HCV. Although the GBV-B/marmoset model has a lower chronicity rate, it has a number of advantages over other animal models including lower cost, availability of chimeric viruses, effectiveness of HCV drugs against GBV-B, and a tractable disease course. While the development of new antivirals has changed the landscape of the HCV field, the cost-prohibitive nature of these treatments underscores the ongoing need for a successful vaccine. Thus, we propose that the GBV-B/marmoset model warrants revisiting as a thoughtful research tool for development of immunotherapeutics, new antivirals, and vaccine modalities for eventual translation into human studies.
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